Published in Proc Natl Acad Sci U S A on May 15, 2006
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res (2009) 1.51
The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer (2013) 1.36
Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet (2009) 1.06
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
New chemically induced skin tumour susceptibility loci identified in a mouse backcross between FVB and dominant resistant PWK. BMC Genet (2007) 0.96
Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus. BMC Genomics (2008) 0.88
A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol (2009) 0.87
New outbred colony derived from Mus musculus castaneus to identify skin tumor susceptibility loci. Mol Carcinog (2010) 0.85
Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc Natl Acad Sci U S A (2012) 0.84
Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. Carcinogenesis (2012) 0.82
The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol (2011) 0.81
Most lung and colon cancer susceptibility genes are pair-wise linked in mice, humans and rats. PLoS One (2011) 0.79
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Rep (2014) 0.75
Quantitation of TGF-β proteins in mouse tissues shows reciprocal changes in TGF-β1 and TGF-β3 in normal vs neoplastic mammary epithelium. Oncotarget (2016) 0.75
Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. J Clin Med (2016) 0.75
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol (2001) 4.87
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 4.64
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell (1996) 3.73
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature (2000) 3.36
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem (1988) 3.13
Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet (1999) 3.08
Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A (1990) 2.72
Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol (2004) 2.53
Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension (1996) 2.44
Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science (1990) 2.22
A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res (2003) 2.21
Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell (1990) 2.16
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature (1988) 1.99
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
Molecular cloning and characterization of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible Sp1-like zinc finger-encoding genes involved in the regulation of cell growth. J Biol Chem (1998) 1.86
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
The Id proteins and angiogenesis. Oncogene (2001) 1.70
Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol (2002) 1.61
Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation (2000) 1.59
Distinct genetic loci control development of benign and malignant skin tumours in mice. Nat Genet (1995) 1.41
The great MYC escape in tumorigenesis. Cancer Cell (2005) 1.25
Epistatic interactions between skin tumor modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res (2001) 1.15
TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest (2002) 1.11
Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev (2005) 1.11
Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression. J Biol Chem (2003) 1.11
Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res (2001) 1.08
A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer (2003) 1.00
Discordant transforming growth factor beta 1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ (1992) 0.90
Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. Genomics (2005) 0.90
Allelotype analysis of mouse skin tumors using polymorphic microsatellites: sequential genetic alterations on chromosomes 6, 7, and 11. Cancer Res (1993) 0.89
Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a smad-dependent pathway J Biol Chem (2000) 0.87
Association of a polymorphism of the transforming growth factor-beta1 gene with blood pressure in Japanese individuals. J Hum Genet (2002) 0.79
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 3.52
Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol (2007) 2.75
Stem-cell hierarchy in skin cancer. Nat Rev Cancer (2003) 2.36
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet (2008) 2.05
Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat Biotechnol (2002) 2.04
Genomic segmental polymorphisms in inbred mouse strains. Nat Genet (2004) 1.93
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci (2012) 1.74
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature (2007) 1.54
Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res (2009) 1.51
TGF beta signaling in health and disease. Nat Genet (2004) 1.48
The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol (2008) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Fetal alcohol exposure impairs Hedgehog cholesterol modification and signaling. Lab Invest (2007) 1.32
Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev (2004) 1.31
Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol (2013) 1.30
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene (2003) 1.28
Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res (2003) 1.27
TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets (2006) 1.24
Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res (2002) 1.23
Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet (2003) 1.22
Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem (2010) 1.21
Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci U S A (2013) 1.16
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun (2012) 1.13
Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol (2010) 1.12
Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol (2004) 1.11
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol (2010) 1.10
The paradoxical TGF-β vasculopathies. Nat Genet (2012) 1.09
Defective retinal vascular endothelial cell development as a consequence of impaired integrin αVβ8-mediated activation of transforming growth factor-β. J Neurosci (2012) 1.08
Genomic approaches to identification of tumour-susceptibility genes using mouse models. Curr Opin Genet Dev (2003) 1.08
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol (2011) 1.08
Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet (2009) 1.06
Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res (2012) 1.05
A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.04
p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene (2005) 1.04
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice. Hum Mol Genet (2003) 1.03
Mutations of TGFbeta signaling molecules in human disease. Ann Med (2006) 1.03
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res (2005) 1.00
Integrating giant microwave absorption with magnetic refrigeration in one multifunctional intermetallic compound of LaFe(11.6)Si(1.4)C(0.2)H(1.7). Sci Rep (2013) 1.00
Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.98
CHADS2 and CHA2DS2-VASc Scores Predict the Risk of Ischemic Stroke Outcome in Patients with Interatrial Block without Atrial Fibrillation. J Atheroscler Thromb (2016) 0.98
Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev (2011) 0.98
Developing novel oncolytic adenoviruses through bioselection. J Virol (2003) 0.97
Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res (2011) 0.96
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun (2013) 0.95
Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice. Oncogene (2005) 0.95
Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev (2013) 0.94
Mouse strain-dependent heterogeneity of resting limbal vasculature. Invest Ophthalmol Vis Sci (2004) 0.93
High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J Biol Chem (2002) 0.92
Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. Genomics (2005) 0.90
Crosstalk between Pten and Ras signaling pathways in tumor development. Cell Cycle (2005) 0.89
Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen. Mol Cell Endocrinol (2009) 0.89
TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development. J Cell Sci (2006) 0.88
Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus. BMC Genomics (2008) 0.88
Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility. PLoS One (2012) 0.88
The genetics of cancer susceptibility: from mouse to man. Toxicol Pathol (2004) 0.87
Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14Ptch(FVB) mice. J Invest Dermatol (2012) 0.86
Tuning magnetic anisotropies of Fe films on Si(111) substrate via direction variation of heating current. Sci Rep (2013) 0.85
Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol (2003) 0.85
Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome (2004) 0.85
Selective activation of estrogen receptor-beta target genes by 3,3'-diindolylmethane. Endocrinology (2010) 0.84
Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc Natl Acad Sci U S A (2012) 0.84
Exceeding natural resonance frequency limit of monodisperse Fe(3)O(4) nanoparticles via superparamagnetic relaxation. Sci Rep (2013) 0.83
Cancer: new-age tumour suppressors. Nature (2002) 0.83
Changes in NK cell counts and receptor expressions and emergence of CD3(dim)/CD56+ cells in HIV-1 infected patients in China. Viral Immunol (2009) 0.83
Differences in natural killer cell quantification and receptor profile expression in HIV-1 infected Chinese children. Cell Immunol (2010) 0.82
Continuous metabolic syndrome risk score for predicting cardiovascular disease in the Chinese population. Asia Pac J Clin Nutr (2012) 0.82
Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proc Natl Acad Sci U S A (2010) 0.82
The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol (2011) 0.81
Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood (2011) 0.81
Improvement of the uniformity and dipole ferromagnetism in Co nanodots assemblies on Pb/Si(111) via step tuned dimensionality variation. Nanotechnology (2010) 0.81
B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum (2009) 0.81
Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res (2009) 0.81
A sweet link between TGFbeta and vascular disease? Nat Genet (2006) 0.79
Multiple self-healing squamous epithelioma (MSSE): rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology. J Invest Dermatol (2013) 0.79
Emergence of peripheral CD3+CD56+ cytokine-induced killer cell in HIV-1-infected Chinese children. Int Immunol (2012) 0.79